Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476111 · ClinicalTrials.gov registry record
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 117
- Enrollment target
NCT01476111: Clinical Trial study, sponsored by GlaxoSmithKline.
NCT01476111 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 117 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476111 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 117 participants
- Enrollment target
Study Summary
This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-07 |
Why NCT01476111 stopped before completion
NCT01476111 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01476111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01476111 about?
NCT01476111 is a clinical study titled "Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer". This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.
What is the current status of trial NCT01476111?
This trial is currently terminated. The enrollment target is 117 participants. The study started on 2011-12. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT01476111?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia